Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
18 Years
N/A
Both
Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Trial Information
Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
This study is to establish a pilot pharmacogenomic program in identifying genetic variation
to predict the safety, toxicity and/or efficacy of drugs. DNA will be extracted from
patients' peripheral blood to study SNPs in DPD, TS, MTHFR, UGT1A1, CYP3A4, CYP3A5, GSTM1,
GSTT1, GSTP1, HO-1, ERCC1, XPD, XRCC1 and EGFR genes. The results of genetic study will be
compared to treatment efficacy and toxicity. The ultimate goal is to use genotype profiles
to provide individualized cancer treatment to improve outcome and decrease toxicity.
Inclusion Criteria:
- Lung, Colorectal and Head and Neck Cancer Patients that have received or plan to
receive chemotherapy as part of their treatment
Exclusion Criteria:
- Colorectal cancer patients that have never received or will not receive chemotherapy
as part of their therapy
- Head and Neck cancer patients that have never received or will not receive
chemotherapy as part of their treatment
- Patients with cancer types other than colorectal or head and neck
- Unable to give informed consent
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Yu-Jui Yvonne Wan, Ph.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Kansas
Authority:
United States: Institutional Review Board
Study ID:
10270
NCT ID:
NCT00442520
Start Date:
February 2006
Completion Date:
September 2008
Related Keywords:
- Lung Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Colorectal Neoplasms
- Head and Neck Neoplasms
- Lung Neoplasms
Name | Location |
|---|---|
| University of Kansas Medical Center | Kansas City, Kansas 66160-7353 |
